Abstract: The present invention is related to a downhole device for hydrocarbon producing wells without conventional tubing (tubingless completion), which improves the hydrocarbon production (gas, oil and condensate), selectively controls produced solids (reservoir sand and hydraulic fracture proppant) and eliminates liquid loading. The device of the present invention is designed according to selected well and reservoir characteristics by an integral methodology which includes the stages: data collection and analysis of the well operating conditions, selection of candidate well, sampling and analysis of produced solids, simulation of production conditions, design and manufacture and installation.

Abstract: This invention relates to lattice tower for actuate under high load conditions, more particularly to lattice towers utilized for wind turbines and other applications comprising three metallic legs arranged in a triangular configuration around a vertical axis of the lattice tower, wherein each metallic leg has a closed cross-section profile, a distance between the center of metallic legs in a bottom portion of the tower is greater than 4 meters, an angle of inclination of a central longitudinal axis of each metallic leg in relation to the vertical axis of the tower is between ?1.7 degree and +1.7 degrees, and the height of the lattice tower is greater than 60 meters, a plurality of bracing members and auxiliary bracing members and a support platform disposed at a top portion of the tower.

Abstract: This invention relates to lattice tower for actuate under high load conditions, more particularly to lattice towers utilized for wind turbines and other applications comprising three metallic legs arranged in a triangular configuration around a vertical axis of the lattice tower, wherein each metallic leg has a closed cross-section profile, a distance between the center of metallic legs in a bottom portion of the tower is greater than 4 meters, an angle of inclination of a central longitudinal axis of each metallic leg in relation to the vertical axis of the tower is between ?1.7 degree and +1.7 degrees, and the height of the lattice tower is greater than 60 meters, a plurality of bracing members and auxiliary bracing members and a support platform disposed at a top portion of the tower.

Abstract: This invention relates to lattice tower for actuate under high load conditions, more particularly to lattice towers utilized for wind turbines and other applications comprising three metallic legs arranged in a triangular configuration around a vertical axis of the lattice tower, wherein each metallic leg has a closed cross-section profile, a distance between the center of metallic legs in a bottom portion of the tower is greater than 4 meters, an angle of inclination of a central longitudinal axis of each metallic leg in relation to the vertical axis of the tower is between ?1.7 degree and +1.7 degrees, and the height of the lattice tower is greater than 60 meters, a plurality of bracing members and auxiliary bracing members and a support platform disposed at a top portion of the tower.

Abstract: This invention relates to lattice tower for actuate under high load conditions, more particularly to lattice towers utilized for wind turbines and other applications comprising three metallic legs arranged in a triangular configuration around a vertical axis of the lattice tower, wherein each metallic leg has a closed cross-section profile, a distance between the center of metallic legs in a bottom portion of the tower is greater than 4 meters, an angle of inclination of a central longitudinal axis of each metallic leg in relation to the vertical axis of the tower is between ?1.7 degree and +1.7 degrees, and the height of the lattice tower is greater than 60 meters, a plurality of bracing members and auxiliary bracing members and a support platform disposed at a top portion of the tower.

Abstract: The present invention refers to analog compounds of peptides having the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, including analgesic peptides derived from snakes of species such as Crotalus durissus terrificus; their uses in the treatment, diagnosis and prevention of painful conditions or mediated by opioid receptors, their pharmaceutical compositions and their methods of preparation and purification, including their uses in the identification of analgesic compounds.

Abstract: Managed access to one or more peripherals of a service terminal is provided. A master controller controls access to the peripheral(s) by applications of the service terminal, wherein only a single application can access the peripheral(s) at a time, by identifying an application of the applications for placing into an on-focus state in order to enable access to the peripheral(s) by the identified application, and placing the identified application into the on-focus state, where access to the peripheral(s) by the identified application is enabled. The remaining applications of the applications execute in an off-focus state in which the master controller simulates, for the remaining applications, connectivity to the peripheral(s), and in which access to the peripheral(s) by the remaining applications is disabled transparent to the remaining applications while the access to the peripheral(s) by the identified application is enabled.

Abstract: Managed access to one or more peripherals of a service terminal is provided. A master controller controls access to the peripheral(s) by applications of the service terminal, wherein only a single application can access the peripheral(s) at a time, by identifying an application of the applications for placing into an on-focus state in order to enable access to the peripheral(s) by the identified application, and placing the identified application into the on-focus state, where access to the peripheral(s) by the identified application is enabled. The remaining applications of the applications execute in an off-focus state in which the master controller simulates, for the remaining applications, connectivity to the peripheral(s), and in which access to the peripheral(s) by the remaining applications is disabled transparent to the remaining applications while the access to the peripheral(s) by the identified application is enabled.

Abstract: The present invention provides oligopeptides with amino acid sequences comprised in set forth in SEQ ID NO 1 to 18, capable of binding to diverse targets, generating increase and sustenance to nitric oxide (NO) production in mammalian cells, potentiate the argininosuccinate synthase activity of animal cells and/or increase the intracellular bivalent calcium ion in animal cells. Also disclosed are pharmaceutical compositions of one or more peptides described in the present invention. The invention further relates to the use of these peptides.

Abstract: The present invention refers to analog compounds of peptides having the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, including analgesic peptides derived from snakes of species such as Crotalus durissus terrificus; their uses in the treatment, diagnosis and prevention of painful conditions or mediated by opioid receptors, their pharmaceutical compositions and their methods of preparation and purification, including their uses in the identification of analgesic compounds.

Abstract: This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions.

Abstract: The present invention is characterized by the process of preparation of pharmaceutical compositions for the development of applications of the Evasins and their structural and/or conformational analogues in chronic-degenerative diseases. It is further characterized by the process of preparation of pharmaceutical compositions and related products of the Evasins peptides and their structural and/or conformational analogues in using the cyclodextrins, its derivatives, liposomes and biodegradable polymers and/or mixture of these systems. The invention is further characterized by the increased efficacy of these peptides and their analogues included in cyclodextrins, when administered to rats. This characterizes an increased biodisponibility of these peptides and their analogues using the compositions of the present invention.

Abstract: This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions.

Abstract: The present invention describes an axial flow fan blade that presents innovation on its shape that results in a lower noise emission and in a higher efficiency. The axial flow fan blade, object of the present patent, has a lower vortex emission than the blades available on the previous art. This lower vortex emission is responsible for a lower level of pressure fluctuations, which results in a lower noise emission, and is also responsible for a lower energy expense on the vortex formation, which results in an efficiency increase. The present axial flow fan blade can be employed in various applications where it is necessary to move any gas.

Abstract: The present invention describes an axial flow fan blade that presents innovation on its shape that results in a lower noise emission and in a higher efficiency. The axial flow fan blade, object of the present patent, has a lower vortex emission than the blades available on the previous art. This lower vortex emission is responsible for a lower level of pressure fluctuations, which results in a lower noise emission, and is also responsible for a lower energy expense on the vortex formation, which results in an efficiency increase. The present axial flow fan blade can be employed in various applications where it is necessary to move any gas.